SBIO ALPS Medical Breakthroughs ETF

ETF 55.09 Delayed

ETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SBIO $55.09 —
Key stats
$55.09
52-Week Range
$40.40 – $70.85
YTD
+9.83%
IV Rank (30D)
96.12
Straddle Price
$5.28
P/C Vol Ratio
0.00
Open
$54.50
Day Range
$54.37 – $55.51
Volume
33,639
Prev Close
$53.95
About

ALPS Medical Breakthroughs ETF (SBIO) ETF

No description available.

Exchange
ARCX
Inception
2014-12-30
Has Options
Yes
Fund profile
holdings as of May 31, 2026SEC filingthrough May 2026flows, SEC filings
Thematic Biotech & Health Innovation#10 of 26 by assets ALPS Internet & Innovation US Index-tracking
Expense ratio
0.50%
prospectus, filed Mar 30, 2026
Assets
$200M
shares × price, Oct 9, 2026
Trailing yield
—
paid annual
Average daily volume
$2.6M
30 sessions
Holdings
89
top 10 are 34.8%
Listed
Dec 30, 2014
NYSE Arca
Closure risk, 12 months
0.7%
low · model
Tracking difference
+0.10 pts
vs index, after fees, FY 2025
FrenzyCap ETF score
57
how it is built
Cost60
Liquidity47
Scale48
Diversification75

Moves with. Small caps over large (15% of its variance, beta 1.02); Value over growth (7% of its variance, beta -0.61); Long Treasuries (6% of its variance, beta 0.63); US large-cap stocks (4% of its variance, beta 0.25). These factors explain 36% of its daily moves over the last year.

Stated objective. The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the Underlying Index). (from the fund's prospectus)

All 89 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs

Fund flows
through May 2026SEC filings
May 2026
+$4.1M
latest reported month
Latest 3 months
+$17M
+10.8% of assets
Latest 12 months
+$24M
+14.5% of assets
Jun 2025: −$4.7MJul 2025: −$9.2MJulAug 2025: −$876KSep 2025: +$1.8MSepOct 2025: −$21M−$21MNov 2025: +$11MNovDec 2025: +$20MJan 2026: +$11MJanFeb 2026: −$1.3MMar 2026: −$7.4MMarApr 2026: +$21M+$21MMay 2026: +$4.1MMay
View as a table
Net flows of SBIO by month, Jun 2025 to May 2026
MonthNet flow
May 2026+$4.1M
Apr 2026+$21M
Mar 2026−$7.4M
Feb 2026−$1.3M
Jan 2026+$11M
Dec 2025+$20M
Nov 2025+$11M
Oct 2025−$21M
Sep 2025+$1.8M
Aug 2025−$876K
Jul 2025−$9.2M
Jun 2025−$4.7M

Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 81 months ago

Similar funds
FundOverlapFeeAssets1Y
BBCVirtus Biotech Clinical Trials ETF31%0.65%$42M+52.3%compare
XBIState Street SPDR S&P Biotech ETF22%0.35%$9.9B+45.8%compare
IBRNiShares Neuroscience and Healthcare ETF19%0.47%$6.4M+13.3%compare
LABUDirexion Daily S&P Biotech Bull 3X ETF18%—$553M+123.0%compare
PTHInvesco Exchange-Traded Fund Trust Invesco Dorsey Wright Healthcare Momentum ETF17%0.60%$355M+29.8%compare

Ranked by how much of the two portfolios is the same securities.

Look-through: what the holdings say
weights as of May 31, 2026SEC filing
Holdings vs fair value
+12.5%
51% under, 19% over · 91% covered
Price / earnings
—
91% loss-making · 95% covered
Price / book · sales
3.5 · 8.0
revenue growth +8.1%
Above 200-day average
43%
5% above 50-day · by weight
Short interest
17.4%
of float, weighted · 8.0 days to cover
Insider buying
9%
of weight had net insider buying, 90 days; 48% net selling
13F holders
+12.0%
change in shares held by institutions, latest quarter
Reporting earnings
0.0%
of weight in 7 days; 0.0% in 14
Implied correlation
0.19
fund IV 37.3% vs holdings 81.8% · board
Largest contributors below fair value
ALKS+43%DNLI+50%VKTX+36%ORKA+46%GPCR+41%
Largest contributors above fair value
TVTX−47%ZLAB−50%TSHA−50%DNTH−17%EWTX−18%

Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.

What changed in the portfolio
Feb 28, 2026 → May 31, 2026
ActionHoldingWeight beforeWeight afterShares vs flows
ExitFOLDAmicus Therapeutics Inc2.86%——
ExitAPLSApellis Pharmaceuticals Inc1.71%——
IncreaseMIRMMirum Pharmaceuticals Inc3.06%3.90%+16.1%
ExitDAWNDay One Biopharmaceuticals Inc0.70%——
IncreaseGPCRStructure Therapeutics Inc2.47%1.78%+15.5%
IncreaseBCAXBicara Therapeutics Inc0.59%0.88%+14.4%
IncreaseCRVSCorvus Pharmaceuticals Inc0.88%0.66%+10.9%
IncreaseCADLCandel Therapeutics Inc0.19%0.39%+32.0%
IncreaseACRSAclaris Therapeutics Inc0.20%0.35%+10.1%
IncreaseVERAVera Therapeutics Inc1.68%1.61%+10.4%

0 new, 3 exited, 10 increased and 0 decreased between the fund's two latest holdings reports; turnover 12.3%. Full holdings and history

Under the hood
fiscal year to Nov 30, 2025SEC census
Authorized participants
5 active
of 5 with agreements; top 3 did 72%
Created · redeemed
$18M · $54M
over the fiscal year
Redemptions in kind
100%
creations 100% in kind
Creation unit
25,000
shares
Securities lending
22.61%
of assets on loan on average; earned 16.4 bp
Return vs index
+0.10 pts
after fees; +0.75 before; daily s.d. 0.42

From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.

ETF Profile
holdings as of 2026-11-30
Holdings
92
AUM
$138.1M
Provider
Nport
Inception
2014-12-30
Exchange
ARCX
Data As Of
2026-11-30
Expense Ratio
0.50%
Dividend Yield
—
Distribution
Annual
Recent distributions
Ex-Date Pay Date Amount Type
2024-12-19 2024-12-26 $1.1735 CD
2023-12-21 2023-12-27 $0.0711 CD
Asset Allocation
Top Holdings
top 50 of 92 holdings
Symbol Name Weight % Asset Class Country
KYMR Kymera Therapeutics Inc 4.66% Equity (common) US
CELC Celcuity Inc 3.34% Equity (common) US
ALKS Alkermes Plc 3.21% Equity (common) IE
CGON Cg Oncology Inc 3.06% Equity (common) US
MIRM Mirum Pharmaceuticals Inc 3.06% Equity (common) US
FOLD Amicus Therapeutics Inc 2.86% Equity (common) US
ACAD Acadia Pharmaceuticals Inc 2.68% Equity (common) US
NAMS Newamsterdam Pharma Co Nv 2.60% Equity (common) NL
CRNX Crinetics Pharmaceuticals Inc 2.52% Equity (common) US
APGE Apogee Therapeutics Inc 2.48% Equity (common) US
VKTX Viking Therapeutics Inc 2.47% Equity (common) US
GPCR Structure Therapeutics Inc 2.47% Equity (common) KY
XENE Xenon Pharmaceuticals Inc 2.16% Equity (common) CA
SYRE Spyre Therapeutics Inc 2.15% Equity (common) US
EWTX Edgewise Therapeutics Inc 2.08% Equity (common) US
TARS Tarsus Pharmaceuticals Inc 2.07% Equity (common) US
DNLI Denali Therapeutics Inc 2.01% Equity (common) US
IDYA Ideaya Biosciences Inc 1.82% Equity (common) US
TVTX Travere Therapeutics Inc 1.72% Equity (common) US
APLS Apellis Pharmaceuticals Inc 1.71% Equity (common) US
VERA Vera Therapeutics Inc 1.68% Equity (common) US
IRON Disc Medicine Inc 1.62% Equity (common) US
DNTH Dianthus Therapeutics Inc 1.53% Equity (common) US
MLYS Mineralys Therapeutics Inc 1.50% Equity (common) US
LKFT Galapagos Nv 1.42% Equity (common) BE
MAZE Maze Therapeutics Inc 1.42% Equity (common) US
ZLAB Zai Lab Ltd 1.39% Equity (common) KY
STOK Stoke Therapeutics Inc 1.34% Equity (common) US
NUVB Nuvation Bio Inc 1.31% Equity (common) US
CLDX Celldex Therapeutics Inc 1.29% Equity (common) US
OLMA Olema Pharmaceuticals Inc 1.23% Equity (common) US
PHVS Pharvaris Nv 1.17% Equity (common) NL
VCEL Vericel Corp 1.17% Equity (common) US
RLAY Relay Therapeutics Inc 1.15% Equity (common) US
TYRA Tyra Biosciences Inc 1.15% Equity (common) US
AGIO Agios Pharmaceuticals Inc 1.14% Equity (common) US
SRPT Sarepta Therapeutics Inc 1.13% Equity (common) US
OCS Oculis Holding Ag 1.09% Equity (common) CH
AMLX Amylyx Pharmaceuticals Inc 1.08% Equity (common) US
ORKA Oruka Therapeutics Inc 1.08% Equity (common) US
NVAX Novavax Inc 1.06% Equity (common) US
IMCR Immunocore Holdings Plc 1.05% Equity (common) GB
SION Sionna Therapeutics Inc 1.05% Equity (common) US
PVLA Palvella Therapeutics Inc 1.03% Equity (common) US
MBX Mbx Biosciences Inc 0.94% Equity (common) US
ZBIO Zenas Biopharma Inc 0.91% Equity (common) US
IMTX Immatics Nv 0.90% Equity (common) NL
RAPP Rapport Therapeutics Inc 0.89% Equity (common) US
CRVS Corvus Pharmaceuticals Inc 0.88% Equity (common) US
TSHA Taysha Gene Therapies Inc 0.80% Equity (common) US
Geographic Breakdown
Chart
Seasonality
'21'22'23'24'25'26Avg
Jan8.91%-20.00%9.58%1.18%-0.93%2.17%0.15%
Feb-5.16%-5.14%-7.39%9.03%-3.68%-1.82%-2.36%
Mar-11.19%0.93%-10.55%-6.09%-4.87%2.87%-4.82%
Apr-0.32%-19.02%8.99%-6.99%9.89%1.42%-1.00%
May-6.14%-13.00%3.27%-0.54%-1.73%1.70%-2.74%
Jun6.03%8.93%-0.75%-1.19%-0.01%22.42%5.91%
Jul-11.84%4.77%1.87%10.83%9.06%-0.25%2.41%
Aug6.89%8.65%-6.81%1.92%6.51%5.19%3.73%
Sep-4.71%-6.66%-10.20%2.74%8.36%-12.80%-3.88%
Oct0.55%1.72%-6.25%0.62%16.32%-2.82%*1.69%
Nov-9.70%0.71%6.13%1.57%13.55%--2.45%
Dec1.66%-1.60%21.65%-15.55%5.76%--2.38%
Total-24.58%-37.04%4.63%-5.15%72.35%15.85%4.34%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $58.85
SMA 50: $63.86
SMA 200: $56.86
Current: $55.04
EMA 12: $56.64
EMA 26: $59.44
MACD: -2.8058 | Signal: -0.3151
BEARISH
ADX (14): 39.45
TREND
+DI: 15.05
−DI: 39.13

Momentum Oscillators

RSI (14): 29.71
OVERSOLD
Stoch %K: 12.74
Stoch %D: 8.83
Williams %R: -77.62

Volume & Volatility

BB Upper: $65.51
BB Lower: $52.19
NEUTRAL
OBV: 258,215
Vol SMA 20: 48,517
Vol ROC: -9.05%
ATR: $1.65
True Range: $1.57
HV 20: 31.1%
HV 30: 28.5%
HV 60: 29.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All SBIO news →
Showing 1–10 of 33
Page 1 of 4

SBIO Options Activity & IV Rank

SBIO IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 37.3%
7-DTE IV: 53.3%
Expected Move: $5.28
7-DTE Move: $2.97
Days to Exp: 42 (2026-11-20)

Options Flow

Call Volume: 3
Put Volume: 0
P/C Volume: —
BULLISH
Call OI: 3
Put OI: 0
P/C OI: —
Total OI: 3

ATM Options Pricing

ATM Call: $2.50
ATM Put: $2.77
Call %: 4.5%
Put %: 5.0%

Chain Summary

Chain Volume: 90
Chain OI: 121
Last Updated: 10/9/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 9 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 9 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)59.0MediumOct 9
IV Rank (30 DTE)96.1HighOct 9
Straddle Price (30 DTE)$5.28Oct 9
Beta Analysis

Risk Metrics

Beta: 0.9914
Alpha: 17.67%
Correlation: 0.4098
R-Squared: 16.8%
Stock Volatility: 31.5%
Market Volatility: 13.0%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time

SBIO Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

73 filers1,255,386 shares$80.68M value
# Filer Shares Value % of Total % of Float Period
1 Bank of America Corp Custodian 419,459 $27.12M 33.61% — 2026-06-30
2 UBS Group AG Custodian 178,799 $11.56M 14.33% — 2026-06-30
3 Wells Fargo & Company Custodian 65,540 $4.24M 5.25% — 2026-06-30
4 CONNORS INVESTOR SERVICES INC 48,137 $3.11M 3.86% — 2026-06-30
5 Morgan Stanley Custodian 39,956 $2.58M 3.20% — 2026-06-30
6 LPL Financial LLC Custodian 37,700 $2.44M 3.02% — 2026-06-30
7 Moran Wealth Management, LLC 34,030 $2.20M 2.73% — 2026-06-30
8 GRIFFIN ASSET MANAGEMENT, INC. 28,699 $1.86M 2.30% — 2026-06-30
9 Raymond James Financial, Inc. Custodian 27,244 $1.76M 2.18% — 2026-06-30
10 FIG FINANCIAL ADVISORY SERVICES INC /ADV 30,165 $1.76M 2.18% — 2026-09-30
11 Stifel Financial Corp Custodian 25,648 $1.66M 2.06% — 2026-06-30
12 Sterling Investment Advisors, Ltd. 23,800 $1.54M 1.91% — 2026-06-30
13 SILVER OAK SECURITIES, INCORPORATED 20,680 $1.34M 1.66% — 2026-06-30
14 NTV Asset Management LLC 17,083 $1.10M 1.37% — 2026-06-30
15 Equitable Holdings, Inc. 15,327 $990.89K 1.23% — 2026-06-30
16 COMMONWEALTH EQUITY SERVICES, LLC 13,057 $844.14K 1.05% — 2026-06-30
17 BOK Financial Private Wealth, Inc. 13,000 $840.45K 1.04% — 2026-06-30
18 Royal Bank of Canada Custodian 11,571 $748.00K 0.93% — 2026-06-30
19 ELEVATION POINT WEALTH PARTNERS, LLC 11,225 $725.70K 0.90% — 2026-06-30
20 DAVENPORT & Co LLC 11,100 $717.62K 0.89% — 2026-06-30
21 Vestmark Advisory Solutions, Inc. 8,898 $575.26K 0.71% — 2026-06-30
22 Prospera Financial Services Inc 8,872 $573.49K 0.71% — 2026-06-30
23 Cambridge Investment Research Advisors, Inc. 8,774 $567.00K 0.70% — 2026-06-30
24 Range Advisory, LLC 8,464 $547.23K 0.68% — 2026-06-30
25 Phoenix Wealth Advisors 8,390 $542.41K 0.67% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.67K
SI % of Float
0.18%
Days to Cover
1.00
Short Vol Ratio
20.5%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-09
SBIO Constituent Performance

Click any bar to view the full quote for that stock.

SBIO Constituents (85 of 85)
Symbol Name Weight % Price 1 Day 1 Week 1 Month
KYMR Kymera Therapeutics Inc 4.66% $112.4 +2.84%+4.67%-2.23%
CELC Celcuity Inc 3.34% $67.94 +0.10%-5.77%-18.59%
ALKS Alkermes Plc 3.21% $40.61 +1.25%-2.73%-11.66%
CGON Cg Oncology Inc 3.06% $63.82 +0.89%-5.28%-11.79%
MIRM Mirum Pharmaceuticals Inc 3.06% $86.01 +5.73%+3.71%-12.43%
FOLD Amicus Therapeutics Inc 2.86% $14.49 +0.21%+0.21%+0.42%
ACAD Acadia Pharmaceuticals Inc 2.68% $19.78 +1.02%-0.85%-28.93%
NAMS Newamsterdam Pharma Co Nv 2.60% $21.57 +1.48%-7.00%-5.37%
CRNX Crinetics Pharmaceuticals Inc 2.52% $84.95 +0.13%+0.20%+1.42%
APGE Apogee Therapeutics Inc 2.48% $135.07 -0.01%+0.09%+0.63%
VKTX Viking Therapeutics Inc 2.47% $28.51 +2.81%-4.78%-10.85%
GPCR Structure Therapeutics Inc 2.47% $25.54 -0.51%-7.70%-33.94%
XENE Xenon Pharmaceuticals Inc 2.16% $36.44 +0.77%-4.16%-37.87%
SYRE Spyre Therapeutics Inc 2.15% $85.69 +7.25%-8.05%-5.42%
EWTX Edgewise Therapeutics Inc 2.08% $39.06 -0.43%-5.65%-12.03%
TARS Tarsus Pharmaceuticals Inc 2.07% $73.16 +1.30%+0.22%-7.75%
DNLI Denali Therapeutics Inc 2.01% $19.45 +4.18%-2.75%-7.78%
IDYA Ideaya Biosciences Inc 1.82% $36.11 +0.14%-3.35%-3.94%
TVTX Travere Therapeutics Inc 1.72% $52.12 +0.16%-8.44%-21.23%
APLS Apellis Pharmaceuticals Inc 1.71% $41.03 -0.07%-0.22%+0.45%
VERA Vera Therapeutics Inc 1.68% $29.88 +0.50%-1.78%-14.75%
IRON Disc Medicine Inc 1.62% $62.06 +2.12%-3.80%-11.42%
DNTH Dianthus Therapeutics Inc 1.53% $82.37 -0.07%-6.62%-22.44%
MLYS Mineralys Therapeutics Inc 1.50% $23.37 +4.42%-1.10%-17.13%
LKFT Galapagos Nv 1.42% $29.73 +0.75%+1.23%+10.89%
MAZE Maze Therapeutics Inc 1.42% $27.11 +4.75%+2.57%+10.20%
ZLAB Zai Lab Ltd 1.39% $24.99 +0.73%+2.71%+3.52%
STOK Stoke Therapeutics Inc 1.34% $24.74 +3.30%-3.43%-14.78%
NUVB Nuvation Bio Inc 1.31% $5 +1.01%-2.72%-17.63%
CLDX Celldex Therapeutics Inc 1.29% $29.89 +2.01%-5.56%-19.00%
OLMA Olema Pharmaceuticals Inc 1.23% $7.82 +0.00%-4.92%-23.48%
PHVS Pharvaris Nv 1.17% $31.1 -0.06%-0.29%-18.20%
VCEL Vericel Corp 1.17% $40.1 +0.12%-0.12%+4.59%
RLAY Relay Therapeutics Inc 1.15% $17.88 +2.70%-5.70%-5.25%
TYRA Tyra Biosciences Inc 1.15% $19.94 -0.15%-2.40%-9.49%
AGIO Agios Pharmaceuticals Inc 1.14% $31.81 -0.34%+0.03%-5.33%
SRPT Sarepta Therapeutics Inc 1.13% $17.85 -1.98%+2.00%-12.71%
OCS Oculis Holding Ag 1.09% $8.34 -3.70%-4.47%-21.02%
AMLX Amylyx Pharmaceuticals Inc 1.08% $28.14 +3.46%+1.26%-11.01%
ORKA Oruka Therapeutics Inc 1.08% $82.11 +6.25%-2.85%-11.12%
NVAX Novavax Inc 1.06% $12.75 +15.80%+21.89%+35.35%
IMCR Immunocore Holdings Plc 1.05% $29.39 +1.03%-1.08%-9.85%
SION Sionna Therapeutics Inc 1.05% $4.9 +0.00%-0.20%-37.58%
PVLA Palvella Therapeutics Inc 1.03% $138.77 +5.66%+4.76%-7.57%
MBX Mbx Biosciences Inc 0.94% $53.24 -0.02%-9.01%-9.79%
ZBIO Zenas Biopharma Inc 0.91% $27.26 +3.89%-3.66%-12.40%
IMTX Immatics Nv 0.90% $7.43 +0.81%-2.11%-15.47%
RAPP Rapport Therapeutics Inc 0.89% $30.65 +2.68%-4.72%-29.73%
CRVS Corvus Pharmaceuticals Inc 0.88% $10.52 +3.04%-3.49%-18.51%
TSHA Taysha Gene Therapies Inc 0.80% $4.49 +1.35%-3.02%-10.56%